"Navigating the Modern News Zoo so you don't have to."
Wednesday, April 2, 2025
Tirzepatide benefits people with obesity, kidney disease and heart failure
The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in JACC.
👉 Full Story
The UNTHINKABLE Happens When Woman Visits Her Husband In Jail... #shorts
- Pope Francis, JD Vance, and the Evening Rain - Kathryn Jean Lopez
- Unraveling the Mysteries of Black Holes and Entropy - Arya Chandran
- Machete-wielding cinnamon bun bandit caught mid-snack, Asheville police say
- 5 Best Credit Repair Companies of April 2025
- Aflac’s Brad Dyslin On Japan’s Investment Shifts, Tariffs, And Insurance M&As - Lawrence Strauss
- The Innovative Approach to Track Small Space Debris - Arya Chandran
Is This the Macbook Killer? Ft. Galaxy Book 5 360!
- Hundreds of thousands, maybe millions, gather at Istanbul rally to protest against Erdogan - MeighTimbol
- New study finds that toxic dust on Mars could pose serious threat to astronauts
- What Causes Glassy Eyes? Plus, Treatment and Prevention - Cristina Mutchler
- ChatGPT Experiences Outage Amid OpenAI's Internal Turmoil - Michael Terry
- Online diabetes self-management programs help participants lower their blood sugar
- In Amsterdam, Anselm Kiefer, War, Destiny, and the German Mind, Oh My - Brian T. Allen
